Vicarious Surgical (RBOT)
OTHER OTC:RBOT
Want to see RBOT full AI Analyst Report?
Top Page
Vicarious Surgical
(OTC:RBOT)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.92
▼(-49.67% Downside)
Action:Reiterated
Date:05/22/26
The score is held down primarily by weak financial fundamentals (no revenue, ongoing losses/cash burn, and a materially reduced equity cushion) and the negative delisting-to-OTC corporate event. Technicals show some short-term strength but longer-term trend damage, while valuation metrics provide little support due to losses and no dividend.
Positive Factors
Narrowing losses and trending lower burn
The company has materially reduced operating losses versus prior years, reflecting sustained cost controls and improved operating efficiency. Over a 2–6 month horizon this reduces near-term financing pressure, extends runway, and raises the odds management can reach commercialization milestones without immediate dilutive raises.
Negative Factors
Materially weakened balance sheet and elevated leverage
A sharply reduced equity cushion and net leverage expose the company to heightened solvency and refinancing risk. With limited capital buffer, adverse execution or commercialization delays could force dilutive financings or restructuring, constraining strategic flexibility over the coming months and complicating long-term scaling.
Read all positive and negative factors
Positive Factors
Negative Factors
Narrowing losses and trending lower burn
The company has materially reduced operating losses versus prior years, reflecting sustained cost controls and improved operating efficiency. Over a 2–6 month horizon this reduces near-term financing pressure, extends runway, and raises the odds management can reach commercialization milestones without immediate dilutive raises.
Read all positive factors
Vicarious Surgical (RBOT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.27M
Dividend YieldN/A
Average Volume (3M)90.39K
Price to Earnings (P/E)―
Beta (1Y)2.17
Revenue GrowthN/A
EPS Growth36.00%
CountryUS
Employees123
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-6.75
Shares Outstanding6,470,228
10 Day Avg. Volume138,739
30 Day Avg. Volume90,387
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap1.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.99
Enterprise Value/Ebitda-0.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.07
Revenue Forecast (FY)N/A
Vicarious Surgical Business Overview & Revenue Model
Company Description
Vicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ...
How the Company Makes Money
As of publicly available information through its pre-commercial stage, Vicarious Surgical’s planned primary revenue model is to generate revenue from (1) sales (or placement) of its surgical robotic system to healthcare providers and (2) recurring...
Vicarious Surgical Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Neutral
The earnings call reflects a company focused on reducing costs and improving operational efficiency, evident from significant reductions in operating expenses and successful fundraising efforts. However, challenges remain with high cash burn and potential disruptions due to outsourcing efforts. Additionally, the company has had to reduce its workforce to control costs.Positive Updates
Significant Reduction in Operating Expenses
Total operating expenses for Q3 2025 were $11.5 million, a 35% decrease compared to $17.8 million in Q3 2024.
Negative Updates
Continued High Cash Burn
The company continues to expect full year 2025 cash burn to be approximately $50 million, with a Q3 cash burn rate of approximately $10.5 million.
Read all updates
Q3-2025 Updates
Positive
Negative
Significant Reduction in Operating Expenses
Total operating expenses for Q3 2025 were $11.5 million, a 35% decrease compared to $17.8 million in Q3 2024.
Read all positive updates
Company Guidance
In the Vicarious Surgical's 2025 Third Quarter Earnings Call, the company outlined its guidance and strategic focus areas. The primary objectives include achieving a design freeze for their production-equivalent system by the end of 2026 and reducing cash burn. Operating expenses for the quarter decreased by 35% to $11.5 million compared to the same period in 2024, with specific reductions in R&D, general and administrative, and sales and marketing expenses. The company reported a GAAP net loss of $11.1 million or $1.86 per share for the quarter. Vicarious Surgical ended the quarter with $13.4 million in cash and investments, and a cash burn rate of approximately $10.5 million. They aim to keep the full-year 2025 cash burn around $50 million, with plans to reduce it further in 2026 through outsourcing and restructuring. Additionally, a registered direct offering post-Q3 added $5.2 million in net proceeds. The company intends to improve communication with stakeholders via updates on LinkedIn and their Investor Relations website.Vicarious Surgical Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
28
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -826.00K | -1.43M | -2.11M | -1.85M | 0.00 | 0.00 |
| EBITDA | -41.04M | -49.54M | -61.12M | -69.19M | 6.47M | -34.80M |
| Net Income | -42.12M | -50.18M | -63.22M | -71.07M | 5.16M | -35.21M |
Balance Sheet | ||||||
| Total Assets | 12.59M | 19.58M | 67.72M | 119.86M | 140.29M | 181.68M |
| Cash, Cash Equivalents and Short-Term Investments | 3.68M | 9.79M | 49.10M | 98.18M | 116.21M | 173.51M |
| Total Debt | 6.82M | 7.79M | 13.79M | 14.83M | 15.69M | 1.34M |
| Total Liabilities | 9.02M | 9.74M | 21.02M | 21.89M | 29.25M | 98.59M |
| Stockholders Equity | 3.57M | 9.84M | 46.70M | 97.97M | 111.05M | 83.09M |
Cash Flow | ||||||
| Free Cash Flow | -39.68M | -45.21M | -50.14M | -63.98M | -66.56M | -34.59M |
| Operating Cash Flow | -39.55M | -45.08M | -49.96M | -62.30M | -61.21M | -33.30M |
| Investing Cash Flow | 32.53M | 32.15M | 6.86M | -45.78M | -5.35M | -1.29M |
| Financing Cash Flow | 5.59M | 5.76M | 8.00K | 44.70M | 9.14M | 192.16M |
Vicarious Surgical Technical Analysis
Neutral
1.82
Price Trends
0.72
Positive
1.37
Negative
3.23
Negative
Market Momentum
0.04
Negative
66.98
Neutral
94.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RBOT, the sentiment is Neutral. The current price of 1.82 is above the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.72, and below the 200-day MA of 3.23, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 66.98 is Neutral, neither overbought nor oversold. The STOCH value of 94.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RBOT.
Vicarious Surgical Risk Analysis
Vicarious Surgical disclosed 77 risk factors in its most recent earnings report. Vicarious Surgical reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vicarious Surgical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $4.05B | 38.98 | 9.13% | ― | 12.40% | ― | |
61 Neutral | $1.27B | -32.77 | 17.98% | ― | 8.94% | 102.92% | |
56 Neutral | $65.24M | -6.31 | 3.68% | ― | -0.32% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $81.10M | -0.93 | -55.88% | ― | 2.01% | 85.71% | |
48 Neutral | $1.60B | -11.17 | -27.70% | ― | 29.26% | -7.59% | |
43 Neutral | $6.27M | -0.16 | -247.60% | ― | ― | 36.00% |
* Healthcare Sector Average
RBOT
Vicarious Surgical
0.95
-5.90
-86.15%
LIVN
LivaNova
73.64
30.46
70.54%
XTNT
Xtant Medical Holdings
0.47
-0.26
-35.26%
INSP
Inspire Medical Systems
44.74
-101.21
-69.35%
OM
Outset Medical
4.26
-14.21
-76.94%
PRCT
PROCEPT BioRobotics
28.93
-28.79
-49.88%
Vicarious Surgical Corporate Events
Shareholder MeetingsStock Split
Vicarious Surgical Shareholders Approve Reverse Stock Split Authorization
Neutral
Apr 8, 2026
On April 8, 2026, Vicarious Surgical Inc. held a special meeting of stockholders at which shareholders representing about 60.68% of the company’s total voting power were present in person or by proxy, establishing a quorum. At the meeting, h...
Business Operations and StrategyDelistings and Listing ChangesFinancial Disclosures
Vicarious Surgical Delisted to OTC as Losses Narrow
Negative
Mar 9, 2026
On March 3, 2026, the New York Stock Exchange moved to suspend and delist Vicarious Surgical’s common stock after the company’s market capitalization fell below the exchange’s $15 million continued listing threshold, and Vicariou...
Business Operations and StrategyExecutive/Board Changes
Vicarious Surgical Implements Executive Salary Reductions, Maintains Incentives
Neutral
Mar 6, 2026
On March 4, 2026, Vicarious Surgical Inc. amended the executive employment agreements of President Adam Sachs and Chief Technology Officer Sammy Khalifa, with both leaders voluntarily agreeing to reduce their annual base salaries to approximately ...
Business Operations and StrategyDelistings and Listing Changes
Vicarious Surgical Announces NYSE Delisting and OTC Transition
Negative
Mar 4, 2026
On March 3, 2026, Vicarious Surgical received notice that the New York Stock Exchange would immediately suspend trading and begin delisting its common stock after the company fell below the exchange’s $15 million average global market capita...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.